Literature DB >> 9274795

On the growth rates of human malignant tumors: implications for medical decision making.

S Friberg1, S Mattson.   

Abstract

Testicular carcinomas, pediatric tumors, and some mesenchymal tumors are examples of rapidly proliferating cell populations, for which the tumor volume doubling time (TVDT) can be counted in days. Cancers from the breast, prostate, and colon are frequently slow-growing, displaying a TVDT of months or years. Irrespective of their growth rates, most human tumors have been found: to start from one single cell, to have a long subclinical period, to grow at constant rates for long periods of time, to start to metastasize often even before the primary is detected, and to have metastases that often grow at approximately the same rate as the primary tumor. The recognition of basic facts in tumor cell kinetics is essential in the evaluation of important present-day strategies in oncology. Among the facts emphasized in this review are: (1) Screening programs. Most tumors are several years old when detectable by present-day diagnostic methods. This makes the term "early detection" questionable. (2) Legal trials. The importance of so-called doctor's delay is often discussed, but the prognostic value of "early" detection is overestimated. (3) Analyses of clinical trials. Such analysis may be differentiated depending on the growth rates of the type of tumor studied. Furthermore, uncritical analysis of survival data may be misleading if the TVDT is not taken into consideration. (4) Analyses of epidemiological data. If causes of malignant tumors in humans are searched for, the time of exposure must be extended far back in the subject's history. (5) Risk estimations by insurance companies. For the majority of human cancers, the 5-year survival rate is not a valid measurement for cure. Thus, basic knowledge of tumor kinetics may have important implications for political health programs, legal trials, medical science, and insurance policies.

Entities:  

Mesh:

Year:  1997        PMID: 9274795     DOI: 10.1002/(sici)1096-9098(199708)65:4<284::aid-jso11>3.0.co;2-2

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  107 in total

1.  Growth rate of chemotherapy-naïve lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection.

Authors:  Koji Kawaguchi; Keisuke Uehara; Goro Nakayama; Takayuki Fukui; Koichi Fukumoto; Shota Nakamura; Kohei Yokoi
Journal:  Int J Clin Oncol       Date:  2015-08-18       Impact factor: 3.402

Review 2.  How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity.

Authors:  Padmashree C G Rida; Guilherme Cantuaria; Michelle D Reid; Omer Kucuk; Ritu Aneja
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

3.  Two week rule: Breast cancer growth rates favour abolition of rule.

Authors:  Emma J Helm; Edward Nash
Journal:  BMJ       Date:  2007-08-25

4.  Poor self-rated health associated with an increased risk of subsequent development of lung cancer.

Authors:  Hilde Kristin Refvik Riise; Trond Riise; Gerd Karin Natvig; Anne Kjersti Daltveit
Journal:  Qual Life Res       Date:  2013-06-17       Impact factor: 4.147

Review 5.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

Authors:  Bert Gold; Milena Cankovic; Larissa V Furtado; Frederick Meier; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2015-05       Impact factor: 5.568

6.  In vivo growth of 60 non-screening detected lung cancers: a computed tomography study.

Authors:  Onno M Mets; Kaman Chung; Pieter Zanen; Ernst T Scholten; Wouter B Veldhuis; Bram van Ginneken; Mathias Prokop; Cornelia M Schaefer-Prokop; Pim A de Jong
Journal:  Eur Respir J       Date:  2018-04-12       Impact factor: 16.671

Review 7.  [Value of galvanotherapy for localised prostate cancer].

Authors:  C Arsov; C Winter; P Albers
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

8.  Modeling progression in radiation-induced lung adenocarcinomas.

Authors:  Hatim Fakir; Werner Hofmann; Rainer K Sachs
Journal:  Radiat Environ Biophys       Date:  2010-01-08       Impact factor: 1.925

9.  Natural growth and disease progression of non-small cell lung cancer evaluated with 18F-fluorodeoxyglucose PET/CT.

Authors:  Jingbo Wang; Pawinee Mahasittiwat; Ka Kit Wong; Leslie E Quint; Feng-Ming Spring Kong
Journal:  Lung Cancer       Date:  2012-07-28       Impact factor: 5.705

Review 10.  [Active surveillance: concept for renal cell carcinoma?].

Authors:  I Tsaur; D Schilling; A Haferkamp
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.